Mc-Val-Cit-PABC-PNP: Technical Guidance for ADC Peptide Linker Workflows

What This Product Solves

Mc-Val-Cit-PABC-PNP (SKU B1003) addresses a critical challenge in antibody-drug conjugate (ADC) synthesis: the need for a reliable, cathepsin B-cleavable peptide linker that enables targeted delivery and controlled intracellular payload release. By leveraging a Val-Cit-PABC motif, this linker allows ADCs to remain stable in circulation but release cytotoxic agents efficiently upon exposure to cathepsin proteases in lysosomes. This selectivity is essential in targeted drug delivery research, especially for workflows modeled after FDA-approved ADCs such as brentuximab vedotin, where precise intracellular release is required. Mc-Val-Cit-PABC-PNP is particularly suited for protocols utilizing organic solvents and where aqueous solubility is not a necessity.

For a detailed technical guide on linker selection and protocol fit, see this technical guide, which reviews optimal workflows for cathepsin B-cleavable ADC linkers. Additional protocol guidance is available in this article, emphasizing setup considerations and solvent compatibility.

Protocol Parameters

• Solubility in DMSO | ≥36.9 mg/mL | Suitable for organic solvent-based ADC conjugation protocols | Ensures adequate linker loading and homogeneous reaction conditions; insolubility in water or ethanol may limit some workflows | product information
• Recommended Storage Temperature | -20°C | All peptide linker stock storage | Maintains chemical stability and purity for extended periods; higher temps may cause degradation | product information
• Purity | 98.00% (as supplied) | Suitable for ADC synthesis and research | High purity minimizes side reactions and inconsistent conjugation efficiency | product information
• Solution Stability | Use freshly prepared; avoid long-term storage | All solution-based protocols | Chemical nature leads to reduced stability in solution; prepare aliquots immediately prior to use | workflow recommendation
• Solvent Compatibility | DMSO (preferred), avoid water/ethanol | Antibody-drug conjugate synthesis | The linker is insoluble in water/ethanol, restricting its use to organic solvent protocols | product information

Workflow Setup and QC Checklist

• Reconstitution: Weigh the required amount of Mc-Val-Cit-PABC-PNP in a dry, clean vessel. Add DMSO (anhydrous) to achieve the desired stock concentration, ensuring complete dissolution by gentle vortexing or pipetting. Do not attempt to dissolve in water or ethanol.
• Aliquoting: Prepare single-use aliquots to minimize freeze-thaw cycles and potential degradation. Store aliquots at -20°C until use.
• Conjugation: Mix the DMSO stock with the antibody or payload solution under optimized molar ratios for ADC synthesis. Gradually introduce the linker to the reaction mixture to prevent precipitation.
• Reaction Monitoring: Use analytical HPLC or LC-MS to confirm conjugation efficiency and monitor for unreacted linker or side products.
• Purification: Employ suitable purification steps (e.g., size exclusion chromatography) to remove free linker and DMSO before downstream analysis.
• Quality Control: Assess final ADC conjugate for payload-to-antibody ratio, stability, and bioactivity as dictated by your research protocol.

Common Failure Modes and Fixes

• Incomplete Dissolution: If the linker does not fully dissolve in DMSO, gently heat (not exceeding 37°C) and vortex. Do not use water or ethanol, as the compound is insoluble in these solvents.
• Linker Degradation: Prolonged storage of Mc-Val-Cit-PABC-PNP solutions can lead to hydrolysis or degradation. Always prepare fresh stocks and avoid repeated freeze-thaw cycles.
• Precipitation During Conjugation: If precipitation occurs upon mixing with aqueous buffers, titrate the DMSO stock slowly into the reaction while maintaining vigorous mixing. Confirm final DMSO concentration is compatible with protein stability.
• Residual DMSO in Product: After conjugation, ensure thorough removal of DMSO by dialysis or chromatography, as residual solvent can affect downstream assays.
• Poor Payload Release: Suboptimal lysosomal cleavage may arise from incorrect linker orientation or insufficient cathepsin B activity; validate cleavage using cell-based or in vitro lysosomal extracts as needed.

Scope and Limitations

Mc-Val-Cit-PABC-PNP is engineered for research applications in antibody-drug conjugate synthesis, specifically where a cathepsin B substrate linker is required for lysosomal cleavage and controlled payload release. Its high solubility in DMSO supports a range of organic solvent-based workflows but precludes use in aqueous formulations or protocols requiring water-soluble linkers. This product is not suitable for diagnostic or clinical therapeutic use. For protocols demanding water compatibility or in vivo evaluation, alternative linkers with appropriate solubility and regulatory status should be considered.

For further details on optimal workflow design and linker selection, see the Technical Guide for ADC Synthesis Workflows, which compares linker performance in organic-solvent based setups.

Conclusion

Mc-Val-Cit-PABC-PNP provides a robust, lysosome-cleavable linker option for targeted drug delivery research and ADC synthesis protocols requiring organic solubility and cathepsin B specificity. When used as directed—dissolved in DMSO, stored at -20°C, and freshly prepared before use—this linker supports reproducible conjugation and payload release profiles. Researchers seeking to buy Mc-Val-Cit-PABC-PNP for non-clinical ADC workflows can rely on its performance in established organic-solvent based systems, as documented by APExBIO and supported in internal technical guidance articles.